Study of dasatinib (BMS-354825) in subjects with chronic myelogenous leukemia with accelerated or myeloid or lymphoid blast phase or Philadelphia chromosome positive acute lymphoblastic leukemia who are resistant to or intolerant of imatinib mesylate

Trial Profile

Study of dasatinib (BMS-354825) in subjects with chronic myelogenous leukemia with accelerated or myeloid or lymphoid blast phase or Philadelphia chromosome positive acute lymphoblastic leukemia who are resistant to or intolerant of imatinib mesylate

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2007

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Dec 2007 Status changed from in progress to completed.
    • 08 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top